The effect of creatine supplementation upon inflammatory and muscle soreness markers after a 30km race.
We have evaluated the effect of a creatine supplementation protocol upon inflammatory and muscle soreness markers: creatine kinase (CK), lactate dehydrogenase (LDH), prostaglandin E2) (PGE2) and tumor necrosis factor-alpha (TNF-alpha) after running 30km. Runners with previously experience in running marathons, with their personal best between 2.5-3h were supplemented for 5 days prior to the 30km race with 4 doses of 5g of creatine and 15g of maltodextrine per day while the control group received the same amount of maltodextrine. Pre-race blood samples were collected immediately before running the 30km, and 24h after the end of the test (the post-race samples). After the test, athletes from the control group presented an increase in plasma CK (4.4-fold), LDH (43%), PGE2 6.6-fold) and TNF-alpha (2.34-fold) concentrations, indicating a high level of cell injury and inflammation. Creatine supplementation attenuated the changes observed for CK (by 19%), PGE2 and TNF-alpha (by 60.9% and 33.7%, respectively, p<0.05) and abolished the increase in LDH plasma concentration observed after running 30km, The athletes did not present any side effects such as cramping, dehydration or diarrhea, neither during the period of supplementation, nor during the 30km race. All the athletes finished the race in a time equivalent to their personal best +/- 5.8%. These results indicate that creatine supplementation reduced cell damage and inflammation after an exhaustive intense race.
Santos
R V T
RV
Laboratory of Metabolism, Institute of Biomedical Sciences, University of São Paulo, Brazil.
Bassit
R A
RA
Caperuto
E C
EC
Costa Rosa
L F B P
LF
D000328:Adult; D000704:Analysis of Variance; D003401:Creatine / Q000494:pharmacology*; D003402:Creatine Kinase / Q000097:blood; D019587:Dietary Supplements; D015232:Dinoprostone / Q000097:blood; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D018763:Muscle Fatigue / Q000502:physiology*; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000293:injuries / Q000502:physiology; D009220:Myositis / Q000503:physiopathology; D012420:Running / Q000502:physiology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D014409:Tumor Necrosis Factor-alpha; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; D015232:Dinoprostone; D003401:Creatine